| Unique ID issued by UMIN | UMIN000057912 |
|---|---|
| Receipt number | R000066199 |
| Scientific Title | Effects of continuous consumption of the test food on visceral fat in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study |
| Date of disclosure of the study information | 2025/05/19 |
| Last modified on | 2025/09/09 15:01:39 |
Effects of continuous consumption of the test food on visceral fat in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Effects of continuous consumption of the test food on visceral fat in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Effects of continuous consumption of the test food on visceral fat in healthy Japanese: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Effects of continuous consumption of the test food on visceral fat in healthy Japanese
| Japan |
Healthy Japanese
| Not applicable | Adult |
Others
NO
To verify the effects of continuous consumption of the test food on visceral fat in healthy Japanese.
Efficacy
Confirmatory
Pragmatic
Not applicable
1. The measured value of visceral fat area at 12 weeks after intervention (12w) [Dose-1 group vs. placebo group]
1. The amount of change from screening (Scr) of visceral fat area at 12w [Dose-1 group vs. placebo group]
2. The measured values and amount of changes from Scr of total fat area and subcutaneous fat area at 12w [Dose-1 group vs. placebo group]
3. The measured values and amount of changes from Scr of total fat area, visceral fat area, and subcutaneous fat area at 12w [Dose-2 group vs. placebo group]
4. The measured values and amount of changes from Scr of body weight, body mass index (BMI), body fat percentage, muscle mass, grip strength (dominant hand and not-dominant hand), total cholesterol (T-Cho), low density lipoprotein-cholesterol (LDL-Cho), high density lipoprotein-cholesterol (HDL-Cho), and triglyceride (TG) at 12w [Dose-1 group vs. placebo group and Dose-2 group vs. placebo group]
5. Individuals who experienced adverse events
6. Individuals whose values of urinalysis and peripheral blood test are outside the reference range after intervention despite within the reference range at Scr
7. Anthropometric measurement, urinalysis, and peripheral blood test
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
Institution is not considered as adjustment factor.
YES
3
Educational,Counseling,Training
| Food |
Duration: 12 weeks
Test product: Test food (Dose-1)
Duration: 12 weeks
Test product: Test food (Dose-2)
Duration: 12 weeks
Test product: Placebo
| 18 | years-old | <= |
| Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
5. Individuals whose BMI is 23 kg/m2 or more and less than 30 kg/m2 at Scr
6. Individuals whose visceral fat area by X-ray CT scan is relatively large at Scr
1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Individuals who cannot regularly take three meals (breakfast, lunch, and dinner) a day
5. Individuals who take dairy products such as milk or cheese at least four times a week
6. Individuals who are restricting their diet or exercising for the purpose of dieting
7. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
8. Individuals who are taking or using medications (including herbal medicines) or supplements
9. Individuals who are allergic to medicines or foods related to the test product, particularly those who are allergic to gelatin
10. Individuals who are pregnant, lactating, or planning to become pregnant during this study
11. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
12. Individuals who are judged as ineligible to participate in this study by the physician
93
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
03-3818-0610
nao@orthomedico.jp
J-OIL MILLS, Inc.
J-OIL MILLS, Inc.
Profit organization
Chiba University
Raffinee International Inc.
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
| 2025 | Year | 05 | Month | 19 | Day |
Unpublished
102
No longer recruiting
| 2025 | Year | 04 | Month | 23 | Day |
| 2025 | Year | 04 | Month | 23 | Day |
| 2025 | Year | 05 | Month | 19 | Day |
| 2025 | Year | 12 | Month | 26 | Day |
| 2025 | Year | 05 | Month | 19 | Day |
| 2025 | Year | 09 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066199